Clarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate)
28 juil. 2022 09h05 HE
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first and only FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., July ...
Clarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate)
18 mai 2022 09h05 HE
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions Clarus plans to list this patent...
Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)
28 avr. 2022 09h05 HE
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions Upon issuance, this patent will be...